235 related articles for article (PubMed ID: 33433787)
1. Lipid metabolic dysregulation is involved in Parkinson's disease dementia.
Dong MX; Wei YD; Hu L
Metab Brain Dis; 2021 Mar; 36(3):463-470. PubMed ID: 33433787
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder.
Dong MX; Hu L; Wei YD; Chen GH
Neurosci Lett; 2021 Feb; 745():135626. PubMed ID: 33440238
[TBL] [Abstract][Full Text] [Related]
3. Integrated Analysis Reveals Altered Lipid and Glucose Metabolism and Identifies NOTCH2 as a Biomarker for Parkinson's Disease Related Depression.
Dong MX; Feng X; Xu XM; Hu L; Liu Y; Jia SY; Li B; Chen W; Wei YD
Front Mol Neurosci; 2018; 11():257. PubMed ID: 30233306
[TBL] [Abstract][Full Text] [Related]
4. Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease.
Mizutani Y; Ohdake R; Tatebe H; Higashi A; Shima S; Ueda A; Ito M; Tokuda T; Watanabe H
J Neurol; 2023 Nov; 270(11):5461-5474. PubMed ID: 37480401
[TBL] [Abstract][Full Text] [Related]
5. High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) Based Quantitative Lipidomics Study of Ganglioside-NANA-3 Plasma to Establish Its Association with Parkinson's Disease Patients.
Zhang J; Zhang X; Wang L; Yang C
Med Sci Monit; 2017 Nov; 23():5345-5353. PubMed ID: 29123078
[TBL] [Abstract][Full Text] [Related]
6. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
Han W; Sapkota S; Camicioli R; Dixon RA; Li L
Mov Disord; 2017 Dec; 32(12):1720-1728. PubMed ID: 28880465
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
[TBL] [Abstract][Full Text] [Related]
8. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
[TBL] [Abstract][Full Text] [Related]
9. Deficit in specific cognitive domains associated with dementia in Parkinson's disease.
Pal A; Pegwal N; Kaur S; Mehta N; Behari M; Sharma R
J Clin Neurosci; 2018 Nov; 57():116-120. PubMed ID: 30150061
[TBL] [Abstract][Full Text] [Related]
10. Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinson's Disease.
Hu L; Dong MX; Huang YL; Lu CQ; Qian Q; Zhang CC; Xu XM; Liu Y; Chen GH; Wei YD
Front Mol Neurosci; 2020; 13():80. PubMed ID: 32714143
[TBL] [Abstract][Full Text] [Related]
11. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
[TBL] [Abstract][Full Text] [Related]
12. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson's Disease.
Hsu YF; Lin SP; Chu YT; Tsai YT; Huang JW; Phoa FKH; Wu RM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542526
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease.
Sinclair E; Trivedi DK; Sarkar D; Walton-Doyle C; Milne J; Kunath T; Rijs AM; de Bie RMA; Goodacre R; Silverdale M; Barran P
Nat Commun; 2021 Mar; 12(1):1592. PubMed ID: 33707447
[TBL] [Abstract][Full Text] [Related]
14. Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson's disease patients with type 2 diabetes mellitus.
Wang T; Yuan F; Chen Z; Zhu S; Chang Z; Yang W; Deng B; Que R; Cao P; Chao Y; Chan L; Pan Y; Wang Y; Xu L; Lyu Q; Chan P; Yenari MA; Tan EK; Wang Q
Aging (Albany NY); 2020 Aug; 12(15):15682-15704. PubMed ID: 32805719
[TBL] [Abstract][Full Text] [Related]
15. Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling.
Zhao H; Wang C; Zhao N; Li W; Yang Z; Liu X; Le W; Zhang X
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():101-108. PubMed ID: 29518718
[TBL] [Abstract][Full Text] [Related]
16. Dementia in Parkinson's disease: diffusion tensor imaging.
Matsui H; Nishinaka K; Oda M; Niikawa H; Kubori T; Udaka F
Acta Neurol Scand; 2007 Sep; 116(3):177-81. PubMed ID: 17714331
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolomics analysis revealed metabolic disorders in Parkinson's disease.
Lan TT; Chang L; Hou LW; Wang ZZ; Li DC; Ren ZH; Gu T; Wang JW; Chen GS
Medicine (Baltimore); 2023 Jun; 102(23):e33715. PubMed ID: 37335671
[TBL] [Abstract][Full Text] [Related]
18. Brain volumetry in Parkinson's disease with and without dementia: where are the differences?
Lee SH; Kim SS; Tae WS; Lee SY; Lee KU; Jhoo J
Acta Radiol; 2013 Jun; 54(5):581-6. PubMed ID: 23474765
[TBL] [Abstract][Full Text] [Related]
19. Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.
Chang KH; Cheng ML; Tang HY; Huang CY; Wu YR; Chen CM
Mol Neurobiol; 2018 Aug; 55(8):6319-6328. PubMed ID: 29294246
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
Fink A; Dodel R; Georges D; Doblhammer G
Mov Disord; 2023 Nov; 38(11):2041-2052. PubMed ID: 37658585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
